The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A–PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine

Thiol-based redox switches

(2014) Bastian Groitl et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

(2014) Walter Becker et al.   CNS & Neurological Disorders-Drug Targets

Plasma DYRK1A as a novel risk factor for Alzheimer’s disease

(2014) N Janel et al.   Translational Psychiatry

Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors

(2013) Kevin Anderson et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Redox regulation of protein kinases

(2013) Thu H. Truong et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Redox regulation of protein kinases

(2013) Aoife Corcoran et al.   FEBS Journal

Mechanism of dual specificity kinase activity of DYRK1A

(2013) Agnes Walte et al.   FEBS Journal

Mirk/dyrk1B Kinase in Ovarian Cancer

(2013) Eileen Friedman   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

(2013) Meera Soundararajan et al.   STRUCTURE

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?

(2012) Breland Smith et al.   ACS Chemical Neuroscience

2012 Alzheimer’s disease facts and figures

(2012)   Alzheimers & Dementia

XDSAPP: a graphical user interface for the convenient processing of diffraction data usingXDS

(2012) Michael Krug et al.   JOURNAL OF APPLIED CRYSTALLOGRAPHY

Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B

(2012) Tania Tahtouh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Resolving Some Old Problems in Protein Crystallography

(2012) P. Evans   SCIENCE

Linking Crystallographic Model and Data Quality

(2012) P. A. Karplus et al.   SCIENCE

REFMAC5 for the refinement of macromolecular crystal structures

(2011) Garib N. Murshudov et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Overview of theCCP4 suite and current developments

(2011) Martyn D. Winn et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Redox Control of Protein Kinase C: Cell- and Disease-Specific Aspects

(2010) Carlotta Giorgi et al.   ANTIOXIDANTS & REDOX SIGNALING

DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles

(2010) Sergi Aranda et al.   FASEB JOURNAL

Activation, regulation, and inhibition of DYRK1A

(2010) Walter Becker et al.   FEBS Journal

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein kinase inhibition of clinically important staurosporine analogues

(2010) Osman A. B. S. M. Gani et al.   NATURAL PRODUCT REPORTS

Oxidation-induced intramolecular disulfide bond inactivates mitogen-activated protein kinase kinase 6 by inhibiting ATP binding

(2010) Y. Diao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

(2010) Yasushi Ogawa et al.   Nature Communications

The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer

(2010) Eileen Friedman   Cancers

Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

(2009) X. Deng et al.   CANCER RESEARCH

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

Function and regulation of Dyrk1A: towards understanding Down syndrome

(2009) Joongkyu Park et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Quantitative Model of Thermal Stabilization and Destabilization of Proteins by Ligands

(2008) Piotras Cimmperman et al.   BIOPHYSICAL JOURNAL

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome

(2008) Fei Liu et al.   FASEB JOURNAL